7-propan-2-yl-3,4-dihydro-2H-pyrano[3,2-b]pyridine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡喃吡啶类
• 英文名称: 7-propan-2-yl-3,4-dihydro-2H-pyrano[3,2-b]pyridine
• 化学式: C₁₁H₁₅NO
• 分子量: 177.24
• InChiKey: RBSGDVGJHQGHKL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Novel Heterocyclic Compounds and Uses Thereof
  申请人：Huang Zilin

  公开号：US20130210818A1

  公开（公告）日：2013-08-15

  New substituted heterocyclic compounds, compositions containing them, and methods of using them for the inhibition of Raf kinase activity are provided. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.

  提供了新的替代杂环化合物，含有它们的组合物，以及使用它们抑制Raf激酶活性的方法。这些新化合物和组合物可以单独使用，也可以与至少一种额外的药物联合使用，用于治疗由Raf激酶介导的疾病，如癌症。
• PLASMA KALLIKREIN INHIBITORS AND USES THEREOF
  申请人：Shire Human Genetic Therapies, Inc.

  公开号：US20210078999A1

  公开（公告）日：2021-03-18

  The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.

  本发明提供了作为血浆激肽酶抑制剂并具有相同理想特性的化合物及其组合物。
• Boron-Containing Diacylhydrazines
  申请人：Intrexon Corporation

  公开号：US20150322092A1

  公开（公告）日：2015-11-12

  The present disclosure provides boron-containing diacylhydrazines having Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein R 1 , R 2 , R 3 , R 4 , and R 5 are defined as set forth in the specification. The present disclosure also provides the use of boron-containing diacylhydrazines is ecdysone receptor-based inducible gene expression systems. Thus, the present disclosure is useful for applications such as gene therapy, treatment of disease, large scale production of proteins and antibodies, cell-based screening assays, functional genomics, proteomics, metabolomics, and regulation of traits in transgenic organisms, where control of gene expression levels is desirable.

  本公开提供具有I式的含硼二酰肼化合物及其药学上可接受的盐和溶剂化物，其中R1、R2、R3、R4和R5的定义如规范中所述。本公开还提供了使用含硼二酰肼化合物的ecdysone受体基础的诱导基因表达系统。因此，本公开适用于基因治疗、疾病治疗、大规模生产蛋白质和抗体、基于细胞的筛选测定、功能基因组学、蛋白质组学、代谢组学和调控转基因生物的特征等应用，其中需要控制基因表达水平。
• Boron-containing diacylhydrazines
  申请人：Intrexon Corporation

  公开号：US10464951B2

  公开（公告）日：2019-11-05

  The present disclosure provides boron-containing diacylhydrazines having Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4, and R5 are defined as set forth in the specification. The present disclosure also provides the use of boron-containing diacylhydrazines is ecdysone receptor-based inducible gene expression systems. Thus, the present disclosure is useful for applications such as gene therapy, treatment of disease, large scale production of proteins and antibodies, cell-based screening assays, functional genomics, proteomics, metabolomics, and regulation of traits in transgenic organisms, where control of gene expression levels is desirable.

  本公开提供了具有式 I 的含硼二酰肼： 及其药学上可接受的盐和溶液，其中 R1、R2、R3、R4 和 R5 的定义如说明书所述。本公开还提供了含硼二酰肼在基于蜕皮激素受体的诱导基因表达系统中的用途。因此，本公开可用于基因治疗、疾病治疗、蛋白质和抗体的大规模生产、基于细胞的筛选测定、功能基因组学、蛋白质组学、代谢组学以及转基因生物的性状调控等需要控制基因表达水平的应用领域。
• US20140274954A1
  申请人：——

  公开号：US20140274954A1

  公开（公告）日：2014-09-18